







**Hormonal receptor status and HER2 status**

**Association between clinico-pathological characteristics and molecular breast cancer subtypes**

Subjects characteristics	Frequency	Percentage (%)	Percentage (%)
<b>Age at diagnosis</b>	<b>50 (mean)</b>	<b>12.6 (sd.)</b>	
<b>Age group</b>			
40	131	26.7	26.7
41-60	264	53.8	80.4
61-80	90	18.3	98.8
81	6	1.2	100
<b>Hospital</b>			
RMH	33	6.7	6.7
KFH	61	12.4	19.1
CHUK	50	10.2	29.3
BDH	347	70.7	100
<b>Menopausal status</b>			
Pre-menopause	180	36.7	36.7
Menopause	150	30.5	67.2
Pos-menopause	161	32.8	100
<b>Health insurance</b>			
CBHI	289	58.9	58.9
RAMA	20	4.1	62.9
Private	61	12.4	75.4
Others	55	11.2	86.6
Unknown	66	13.4	100
<b>Nationality</b>			
Rwanda	435	88.6	88.6
Foreigner	56	11.4	100
Total	491	100	-

**Note:** RMH: Rwanda Military Hospital; KFH:King Faisal Hospital; CHUK:Centre Hospitalier Universitaire De Kigali; BDH: Bungoma District Hospital; CBHI: Community Based Health Insurance; RAMA: The Rwandaise D'assurance Maladie

**Table 1:** [Obscured text]



--	--	--	--	--	--

## References

in low grade and high grade sinonasal adenocarcinoma: a national  
Benefit from adjuvant tamoxifen therapy in primary breast cancer

Breast cancer prognostic classification in the molecular era: the role of

Meta-analysis of gene expression profiles in breast cancer: toward  
a unified understanding of breast cancer subtyping and prognosis

. Exon patterns findings from a tertiary cancer center